MEDICAMEN Biotech Limited



Date: 14.08.2024

Regd. & Corp. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi - 110019 (INDIA) Tel.: 011 - 47589500-51 (50 Lines), E-mail: info@medicamen.com Web: www.medicamen.com CIN No.: L74899DL1993PLC056594

Ref: STEX/Results/Published-2024-25

To

BSE Limited Floor 25, P J Towers Dalal Street Mumbai-400001 National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051

BSE Code-531146

NSE Code: MEDICAMEQ

Sub.: Copy of Publication for Un-Audited Financial Results for the quarter ended on June 30, 2024

Dear Sir,

Pursuant to regulation 30 & 47 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 ("the Regulations"), please find enclosed newspaper cutting with regard to the publication of extract of Un-Audited Financial Results of the Company for the quarter ended on June 30, 2024 approved by the Board of Directors at their Meeting held on 1308.2024.

The copy of the results published in the Financial Express and Jansatta dated August 14, 2024 is enclosed.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,

For Medicamen Biotech Limited

Parul Choudhary Company Secretary ACS-44157

Encl: As above.

CIN:-L22222UP2011PLC103611

3.20

14.37

pared in accordance with The Indian Accounting Standards ("Ind AS") prescribed under section 133 of with the relevant rules issued thereunder.

wed by the Audit Committee and taken on record at the meeting of the Board of Directors at their 3th August 2024 and limited review of these results has been carried out by the Statutory Auditors of

letailed format of un-audited Financial Results filed with the Stock Exchanges under Regulation 33 of nd Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available tes (www.nseindia.com) and also on the Company's website at www.consofinvest.com.

for Consolidated Finvest & Holdings Limited Sanjiv Kumar Agarwal Managing Director - DIN: 01623575



CIN: L24111UR1985PLC015063

d. Office: Sohan Nagar, P.O. Charubeta, Khatima-262308, Distt. Udham Singh Nagar, Uttarakhand 5943) 250153-57, Fax: (05943) 250158, Website - www.esterindustries.com, Email - investor@ester.in

OF AN UN- AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE 2024

(Rs. in Lacs)

	Standalone				Consolidated					
*	Current quarter ended	quarter quarter		Corresponding quarter ended in the previous year	Current quarter ended	Preceeding quarter ended	Previous year ended	Corresponding quarter ended in the previous year		
	30-Jun-24	31-Mar-24	31-Mar-24	30-Jun-23	30-Jun-24	31-Mar-24	31-Mar-24	30-Jun-23		
	(Unaudited)	(Audited) (Refer Note No. 3)	(Audited)	(Unaudited)	(Unaudited)	(Audited) (Refer Note No. 3)	(Audited)	(Unaudited)		
	24,377.02	22,025.56	88,165.58	20,647.45	29,235.7	27,995.05	1,09,046.28	26,698.39		
e tax, ns)	(260.11)	(1,196.30)	(5,728.82)	(674.87)	(1,665.61)	(2,652.28)	(13,500.08)	(2,353.72)		
tax (after	(260.11)	(1,196.30)	(5,728.82)	(674.87)	(1,665.61)	(2,652.28)	(13,500.08)	(2,353.72)		
ax (after ns)	(204.19)	(916.25)	(4,333.43)	(527.63)	(1,609.69)	(2,372.23)	(12,104.69)	(2,206.48)		
eriod f (after tax) er tax)]	(208.11)	(988.62)	(4,409.98)	(529.06)	(1,614.11)	(2,430.84)	(12,181,11)	(2,212.45)		
	4,697.70	4,697.70	4,697.70	4,169.69	4,697.70	4,697.70	4,697.70	4,169.69		
erve) as f the		**************************************	77,925.67				67,056.66			
	(0.22) (0.22)	(1.09) (1.09)	(5.19) (5.19)	(0.63) (0.63)	(1.71) (1.71)	(2.83) (2.83)	(14.49) (14.49)	(2.65) (2.65)		

(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, these standalone financial results ("financial ne 2024 have been reviewed and recommended for approval by the Audit Committee and accordingly have been approved by WEDNESDAY, AUGUST 14, 2024

WWW.FINANCIALEXPRESS.COM



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019 CIN: L74899DL 1993PLC056594 E-mail: cs@medicamen.com, www.medicamen.com

Un-audited standalone and consolidated financial results for the quarter ended as on 30th June 2024

Rupees in Lacs(Except per Share data)

		Standalone				Consolidated				
SI. No.	Particulars	Three months period ended			Year ended	Three months period ended			Year ended	
		Un-audited 30.06.2024	Audited 31.03.2024	Un-audited 30.06.2023	Audited .31.03.2024		Audited 31.03.2024	Un-audited 30:06.2023	Audited 31.03.2024	
1	Total income from operations (net)	4205.69	4555.04	4088.26	17468.88	4363.49	4788.57	4232.23	18163.19	
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	301.51	372.51	515.33	1688.79	155.63	265.56	468.33	1307.56	
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	301.51	372.51	515.33	1688.79	155.63	265.56	468.33	1307.56	
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	225.70	310.31	441.70	1329.80	79.87	204.04	394.70	949.40	
5	Total comprehensive income for the period {Comprising Profit/(loss) for the period (after tax) and other Comprehensive income (after tax)}	225.70	310.31	441.70	1329.80	79.87	204.04	394.70	949.40	
6	Equity Share Capital	1271.46	1271.46	1265.11	1271,46	1271.46	1271.46	1265.11	1271.46	
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)	Darring	1							
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operation)				~ t					
	Basic:	1.78	2.45	3.49	10.50	0.63	1.61	3.12	7.50	
	Diluted:	1.78	2.45	3.49	10.50	0.63	1.61	3.12	7.50	

- The Un-audited financial results for the quarter ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 13 August 2024
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section. 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 -Earning per Share
- Limited review report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For Medicamen Biotech Limited

Sd/-

Place: New Delhi Date: 13.08.2024

Rahul Bishnoi Chairman

TOPASS -LEADER IN EXPRESS-

TCI EXPRESS LIMITED CIN: L62200TG2008PLC061781

Regd. Office: Flat Nos. 306 & 307, 1-8-271 to 273, Ashoka Bhoopal Chambers,

S.P. Road, Secunderabad - 500 003, Telangana

Corp. Office: TCl House, 69, Institutional Area, Sector-32, Gurugram-122 001, Haryana Tel.: + 91 124 2384090-94, E-mail: secretarial@tciexpress.in, Website: www.tciexpress.in

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

(Rs. in Crores except as stated otherwise)

			Standalone		Consolidated			
		Quarter Ended		Year Ended	. Quarter Ended		Year Ended	
Sr. No.	Particulars	30th Jun,	30th Jun.	31st Mar,	30th Jun.	30th Jun.	31st Mar.	



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019 CIN: L74899DL 1993PLC056594 E-mail: cs@medicamen.com, www.medicamen.com

Un-audited standalone and consolidated financial results for the quarter ended as on 30th June 2024

Rupees in Lacs(Except per Share data)

CI		Standalone				Consolidated			
SI. No.	Particulars	Three months period ended			Year ended	Three months period ended			Year ended
	A Company of the Comp	Un-audited 30.06.2024	Audited 31.03.2024	Un-audited 30.06.2023	Audited 31.03.2024	Un-audited 30.06.2024	Audited * 31.03.2024	Un-audited 30.06.2023	Audited 31.03.2024
1	Total income from operations (net)	4205.69	4555.04	4088.26	17468.88	4363.49	4788.57	4232.23	18163.19
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	301.51	372.51	515.33	1688.79	155.63	265.56	468.33	1307.56
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	301.51	372.51	515.33	1688.79	155.63	265.56	468.33	1307.56
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	225.70	310.31	441.70	1329.80	79.87	204.04	394.70	949.40
5	Total comprehensive income for the period {Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax)}	225.70	310.31	441.70	1329.80	79.87	204.04	394.70	949.40
6	Equity Share Capital	1271.46	1271.46	1265.11	1271.46	1271.46	1271.46	1265.11	1271.46
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)						12/11/0	1200,11	12) 1.40
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)		913.4		ugusti.				i de la constante de la consta
	Basic:	1.78	2.45	3.49	10.50	0.63	1.61	3.12	7.50
	Diluted:	1.78	2.45	3.49	10.50	0.63	1.61	3.12	7.50

- The Un-audited financial results for the quarter ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 13 August 2024
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 -Earning per Share Limited review report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For Medicamen Biotech Limited

Sd/-Rahul Bishnoi

Chairman

Place: New Delhi Date: 13.08.2024